Evaluation of the Impact of an Amoxicillin and Amoxicillin/Clavulanic Acid Resistant Probiotic on Key Clinical Outcomes in Children Treated With Amoxicillin or Amoxicillin/Clavulanic Acid - Trial NCT05840588
Access comprehensive clinical trial information for NCT05840588 through Pure Global AI's free database. This phase not specified trial is sponsored by Liaquat University of Medical & Health Sciences and is currently Recruiting. The study focuses on Bacterial Infections. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Liaquat University of Medical & Health Sciences
Timeline & Enrollment
N/A
Apr 10, 2023
Dec 31, 2023
Primary Outcome
Incidence of any Gastrointestinal upset
Summary
Amoxicillin or Amoxicillin/Clavulanic acid antibiotic therapy has been shown to be associated
 with disrupting the microbiota population particularly Bifidobacterium, which may have
 further GI clinical implications.
 
 The present randomized clinical trial is aimed to assess if probiotic Bifidobacterium breve
 PRL2020 can help modulate the Bifidobacterium population and its clinical implications after
 antibiotic Amoxicillin or Amoxicillin/Clavulanic acid antibiotic therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05840588
Non-Device Trial